Novo Nordisk'sMedical Miracle

摘要

Novo Nordisk Chief Executive Lars Rebien Sorensen made a bold decision four years ago. His company had made its name selling one 90-year-old miracle drug—insulin for diabetes. Rival drug companies were testing new diabetes pills that threatened to cut into insulin's market share. One such pill from Merck had just been approved in the U.S. Others seemed imminent Worse, Novo Nordisk had spent $1 billion to come up with its own diabetes pills with limited success.